Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Quantitative Metabolome Profiling Reveals Novel Potential Biomarkers
in Human Herpesvirus 6 EncephalopathyYoshihiko Kawano1, MD, Yuka Torii1, MD, Hajime Sato2, Tamaki Fujimori2, PhD, Kazunori Sasaki2,
Jun-ichi Kawada1, MD, PhD, Yoshiaki Ohashi2, PhD, and Yoshinori Ito1, MD, PhD1Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya; and 2Human Metabolome Technologies, Inc., Tsuruoka, Japan
Contact Information
Address: 65 Tsurumai-cho,
Showa-ku, Nagoya
466-8550,
Japan
Tel: +81-52-741-2111
Fax: +81-52-744-2974
e-mail: [email protected]
u.ac.jp
Hoshino et al. Brain Dev. 2012
Pathogens of Acute Encephalopathy
during 2007-2010 in Japan Primary infection with human herpesvirus (HHV)-6
causes roseola (exanthema subitum), occasionally
with accompanying neurological complications such
as febrile seizures and acute encephalopathy, for
which the pathology remains unclear
Metabolomics is a remarkable method that searches
for disease-specific biomarkers by comprehensive
analysis of the kinetics of metabolites, resulting in an
assessment of disease pathophysiology
Metabolome profiling was used to identify novel
biomarkers in HHV-6 encephalopathy
Introduction What are Metabolites…? CE-MS-based Metabolomics
Results
Genome Transcriptome Proteome Metabolome
Human: 22,000 <1,000,000<100,0001122 (serum)
458 (urine), 309 (CSF)
The Human Metabolome Database
GENOMICS
Gene-omics
TRANSCRIPTOMICS
Transcript-omics
PROTEOMICS
Protein-omicsMETABOLOMICS
Metabolite-omics
mRNA Protein PhenotypeDNA
The technologies of genomics, transcriptomics, and
proteomics have been widely used in many studies.
The target of metabolomics is the metabolome, consisting
of metabolites, which are low-molecular weight
intermediates in metabolism.
Migration time (min)
Mass
/ c
harg
e (
m/z)
Target
compounds
MS range: m/z 50-1,000
Run time: 30 min
Capillary Electrophoresis-Time of Flight MS
(CE-TOFMS)
Features of Capillary Electrophoresis
Target Compounds of MS-based Metabolomics
HHV-6
Encephalopathy*
(n=9)
Febrile
Seizure†
(n=20)
Control#
(n=7)
Sex (Male/Female) 3/6 12/8 2/5
Age, mean years SD
(median)
1.1 0.4
(1.0)
2.0 1.4
(1.5)
2.6 2.0
(2.3)
Sample preparation
CE-TOFMS analysis
Metabolite peak information based on m/z and migration time
Hierarchical Cluster Analysis (HCA), Principal Component Analysis (PCA)
Metabolome-wide pathway
Extraction
Inactivation of enzymes
50 μL serum from a patient
HHV-6 infection was defined by either the detection of HHV-6 DNA from the CSF or serum in the early stage of
the disease. Encephalopathy was defined as showing altered consciousness or loss of consciousness that
persisted for more than 24 hours.
Febrile seizure included HHV-6 infection and non-HHV-6 infection.
Control was non-HHV-6 infection without febrile seizure.
*
†
#
Introduction, Materials & Methods
Metabolic Profile in a K yn u renine Pathway
159 metabolites were identified in the serum
samples, and of those, 56 metabolites were
absolutely quantified.
Results of Metabolite Measurements
Rel. Area Mann-Whitney U test Kruskal-Wallis test
Compound name
HHV-6
EncephalopathyFebrile Seizure Control
HHV-6
Encephalopathy
vs.
Febrile Seizure
HHV-6
Encephalopathy
vs.
Control
Febrile Seizure
vs.
Control
Mean S.D. Mean S.D. Mean S.D. Ratio ¶ p-value Ratio ¶ p-value Ratio ¶ p-value p-value
HHV-6 Encephalopathy > Febrile Seizure
Kynurenine 1.8 x 10-3 5.7 x 10-4 1.1 x 10-3 3.0 x 10-4 9.8 x 10-4 4.1 x 10-4 1.6 0.001 1.8 0.013 1.2 0.304 0.003
Quinolinic acid 1.9 x 10-4 8.9 x 10-5 1.0 x 10-4 3.8 x 10-5 8.0 x 10-5 3.7 x 10-5 1.9 0.002 2.4 0.003 1.3 0.255 0.002
3-Aminobutyric acid 1.7 x 10-3 1.4 x 10-3 7.4 x 10-4 4.0 x 10-4 1.2 x 10-3 8.6 x 10-4 2.3 0.001 1.4 0.580 0.6 0.255 0.013
Pipecolic acid 5.9 x 10-4 2.6 x 10-4 3.3 x 10-4 1.1 x 10-4 4.4 x 10-4 2.1 x 10-4 1.8 0.006 1.3 0.338 0.7 0.232 0.024
HHV-6 Encephalopathy < Febrile Seizure
Tryptophan 1.3 x 10-2 5.5 x 10-3 1.9 x 10-2 3.7 x 10-3 1.5 x 10-2 4.9 x 10-3 0.7 0.008 0.9 0.392 1.3 0.069 0.016
cis-Aconitic acid 7.4 x 10-4 1.1 x 10-4 1.0 x 10-3 2.7 x 10-4 8.0 x 10-4 2.6 x 10-4 0.7 0.000 0.9 0.580 1.3 0.126 0.004
Isocitric acid 5.8 x 10-4 8.4 x 10-5 7.2 x 10-4 1.5 x 10-4 6.4 x 10-4 3.0 x 10-4 0.8 0.009 0.9 0.392 1.1 0.112 0.030
Butyric acid 1.3 x 10-3 3.5 x 10-4 1.9 x 10-3 4.3 x 10-4 1.5 x 10-3 5.1 x 10-4 0.7 0.001 0.8 0.244 1.2 0.100 0.005
Hexanoic acid 1.0 x 10-3 2.8 x 10-4 1.3 x 10-3 2.2 x 10-4 1.3 x 10-3 1.6 x 10-4 0.8 0.011 0.8 0.033 1.0 0.707 0.026
Aspartic acid 4.7 x 10-3 1.2 x 10-3 6.9 x 10-3 2.3 x 10-3 6.6 x 10-3 2.3 x 10-3 0.7 0.006 0.7 0.044 1.0 0.788 0.020
Taurine 1.9 x 10-3 6.0 x 10-4 2.9 x 10-3 8.9 x 10-4 2.9 x 10-3 1.4 x 10-3 0.7 0.003 0.7 0.338 1.0 0.518 0.025
m-Toluic acid
o-Toluic acid4.9 x 10-3 1.5 x 10-3 6.2 x 10-3 1.2 x 10-3 7.0 x 10-3 1.5 x 10-3 0.8 0.013 0.7 0.033 0.9 0.255 0.019
Glu-Gly
Gly-Glu2.5 x 10-4 8.8 x 10-5 4.6 x 10-4 3.0 x 10-4 5.3 x 10-4 4.3 x 10-4 0.5 0.002 0.5 0.226 0.9 0.933 0.023
¶ The latter was calculated as denominator
Metabolites Up-regulated/Down-regulated, Comparing HHV-6 Encephalopathy and Febrile Seizure
HHV-6 encephalopathy > Febrile seizure
4 metabolites
Kynurenine, Quinolinic acid,
3-Aminobutyric acid, Pipecolic acid
HHV-6 encephalopathy < Febrile seizure
9 metabolites
Trytophan, cis-Aconitic acid, Isocitric acid,
Butyric acid, Hexanic acid, Aspartic Acid, Taurine,
m-Toluic acid/o-Toluic acid, Glu-Gly/Gly-Glu
0
2
3
4
5
6
7
Co
nc
en
tra
tio
n (
μM
)
1
HHV-6
Encephalopathy
Febrile
SeizureControl
P=0.001
P=0.013
Kynurenine Quinolinic acid
0
0.5
1
1.5
2
2.5
3
4.5
Co
nc
en
tra
tio
n (
μM
)
4
3.5
HHV-6
Encephalopathy
Febrile
SeizureControl
P=0.003
P=0.002
0
0.005
0.01
0.015
0.02
0.025
0.03
Tryptophan
Re
l. A
rea
HHV-6
Encephalopathy
Febrile
SeizureControl
P=0.008
Kynurenine showed
higher levels in the HHV-
6 encephalopathy group
than in both the febrile
seizure group and the
control group.
Quinolinic acid showed
higher levels in the HHV-
6 encephalopathy group
than in both the febrile
seizure group and the
control group.
Tryptophan showed lower
levels in the HHV-6
encephalopathy group
than in the febrile seizure
group.
Discussion
HHV-6 Infection and Kynurenine PathwayTRYPTOPHAN
Kynurenine
3-hydroxykynurenine
3-hydroxyanthranilic acid
Quinolinic acid
Nicotinamide adenosine dinucleotide
(NAD+)
Indoleamine or Tryptophan
2,3-dioxygenase
(IDO,TDO)
neurotoxicityNMDA
receptor
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Serotonin
Rel. A
rea
x 10-4
HHV-6Encephalopathy
FebrileSeizure
Control
0
0.5
1
1.5
2
2.5
3
3.5x 10-4
Rel. A
rea
Indole-3-acetic acid
HHV-6Encephalopathy
FebrileSeizure
Control
0
0.5
1
1.5
2
2.5
3
3.5
Quinolinic acid
Rel. A
rea
x 10-4
HHV-6Encephalopathy
FebrileSeizure
Control
P=0.003
P=0.002
0
0.5
1
1.5
2
2.5
3
Kynurenine
Rel. A
rea
x 10-3
HHV-6
Encephalopathy
Febrile
SeizureControl
P=0.001
P=0.013
0
0.005
0.01
0.015
0.02
0.025
0.03
Tryptophan
Rel. A
rea
HHV-6
Encephalopathy
Febrile
SeizureControl
P=0.008
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D. N.D. N.D.
N.D.
N.D.
N.D.N.D.
N.D.N.D.
Heyes CNS bacterial infection CSF Quinolinic acid
1995 Intraventricular hemorrhage
J Neurol Sci. Brain tumor
Valle HIV-associated neurocognitive disorder CSF Quinolinic acid
2004
Brain.
Valle Amyotrophic lateral sclerosis (ALS) Serum Quinolinic acid
2004 CSF Kynurenine
Brain.
Torii Influenza-associated encephalopathy Serum Quinolinic acid
IDWeek 2013 Kynurenine
Presentation Number 1200
The Kynurenine Pathwayin Neurological Disorders
Conclusion
Metabolite profiles of serum from patients with
HHV-6 encephalopathy were investigated
using CE-TOFMS
Metabolome profiling revealed 13 metabolites
including kynurenine and quinolinic acid as
potential biomarkers for HHV-6
encephalopathy
The tryptophan-kynurenine metabolic process
could be associated with the pathophysiology
of HHV-6 encephalopathy
Principal Component Analysis
Control
HHV-6 Encephalopathy
Febrile Seizure
-6 -4 -2 0 2 4 6 8 10-8
-6
-4
-2
0
2
4
6
8
10
12
PC1 (12.2%)
PC
2 (
9.7
%)
Principal component analysis
was performed. The score plots
for each group showed partial
discriminative separation of the
subjects, with groups showing
some clustering although they
were not clearly divided.
Hierarchical Cluster Analysis
HHV-6
Encephalopathy
Febrile
Seizure
Control
The profiles of the levels of metabolites appeared to be
different among the groups.
0 1 2 3 4 5 6 7
0
1
2
3
4
5
Kynurenine [μM]
Qu
ino
lin
ic a
cid
[μ
M]
§R=0.793 (P<0.01)
Control
HHV-6 Encephalopathy
Febrile Seizure
Correlation between Kynurenine and Quinolinic acid
§Pearson’s correlation coefficient
analysis
Kynurenine and quinolinic acid
were significantly correlated.
Encephalopathy
HHV-6 infection Cytokine
Metabolic Profiles
in Kynurenine
Pathway